Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Broad based selling hits markets
Thu, 21 Nov 11:30 am

After opening weak, the Indian Indices are trading well below the dotted line in the morning session. All sectoral indices are trading in the red. The selling pressure is the highest in Capital Goods and Banking stocks.

The BSE Sensex is down 240 points and the NSE-Nifty is trading down 73 points. The BSE Mid Cap index is trading down 0.5% and the BSE Small Cap index is trading up 0.4%. The Rupee is trading at 62.88 to the US Dollar.

Most Telecom stocks are trading lower today. Tata Teleservices and Reliance Communications are among the stocks leading the losers. According to a leading financial daily, India's leading telecom company Bharti Airtel, is looking to upgrade its infrastructure for 3G services. It has floated a request for proposal (RFP) to select a supplier which can provide high quality 3G network solutions. Bharti wants these network solutions to be compliant in both 900MHz and 1800MHz bands as there is no clarity on the government's re-farming policy yet. Bharti which added 1.49 m customers in October holds the 900 MHz spectrum in Mumbai, Delhi and Kolkata. These would be up for renewal next year and the company would have to vacate this spectrum and bid for them again. Once the re-farming issue is settled, the company would take a call, to ask for a final bid on either the 900MHz or 1800 MHz bands. Bharti Airtel is trading down 1.4% today.

Indian Pharma stocks are trading mixed today. Dishman Pharma and Strides Arcolab Ltd. are leading the gainers. Panacea Biotec Ltd and Sun Pharmaceuticals are leading the losers. According to a leading business daily, Ipca Laboratories plans to start making active pharmaceutical ingredients (APIs) for male hormones from its Nandesari facility near Vadodara in Gujarat. The company has already started making API for one female hormone product from last month and has a long term plan to commercially launch 15 female hormone APIs. Also, Ipca's recent acquisition of 50% stake in Avik Pharmaceuticals Ltd will help the company reduce the cycle time for their launch of hormone products. This is because Avik has the required expertise to manufacture male and female hormone products. IPCA has invested about Rs 500 m on the Nandesari facility in the last one and a half years in order to make APIs. According to the company, for time being it will source APIs from Avik's Vapi facility and sell it in Indian market as well as the rest of world (ROW) markets. IPCA is trading up by 0.5% today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Broad based selling hits markets". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.